Alberto BALLESTRERO,Irene CAFFA,Valter LONGO,Alessio NENCIONI,Patrizio ODETTI,Franco PATRONE
申请号：
US15129569
公开号：
US20170173020A1
申请日:
2015.03.30
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period； the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
